Axitinib
Catalog No: 52771
CAS Number: 319460-85-0
Purity: 98%
Axitinib, also known as AG013736, is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. A xitinib has received FDA (27 January 2012), EMA (13 September 2012), MHRA (3 September 2012) and TGA (26 July 2012) approval for use as a treatment for renal cell carcinoma.
For research use only. We do not sell to patients.
Chemical Information
| Name | Axitinib |
|---|---|
| Molecular Formula | C22H18N4OS |
| Molecular Weight | 386.47 |
| Smile | CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4 |
| InChiKey | RITAVMQDGBJQJZ-FMIVXFBMSA-N |
| InChi | InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ |
| CAS Number | 319460-85-0 |
| MDL | MFCD09837898 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Purity | 98% |
|---|---|
| Solubility | Soluble to 25 mM in DMSO |
| Handling | |
| HS Code |
Coming soon.
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
Not available
Chemical Structure
